{"id":"NCT03358147","sponsor":"Pearl Therapeutics, Inc.","briefTitle":"Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma","officialTitle":"A Randomized, Double-Blind, Parallel Group, Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistent Asthma","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2017-12-13","primaryCompletion":"2019-09-12","completion":"2019-09-12","firstPosted":"2017-11-30","resultsPosted":"2020-08-12","lastUpdate":"2020-08-12"},"enrollment":1077,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"GP MDI 28.8 μg","otherNames":["GP"]},{"type":"DRUG","name":"GP MDI 14.4 μg","otherNames":["GP"]},{"type":"DRUG","name":"GP MDI 7.2 μg","otherNames":["GP"]},{"type":"DRUG","name":"Placebo MDI","otherNames":["Placebo"]},{"type":"DRUG","name":"Spiriva Respimat 2.5 μg","otherNames":["Spiriva Respimat"]}],"arms":[{"label":"GP MDI 28.8 μg","type":"EXPERIMENTAL"},{"label":"GP MDI 14.4 μg","type":"EXPERIMENTAL"},{"label":"GP MDI 7.2 μg","type":"EXPERIMENTAL"},{"label":"Placebo MDI","type":"PLACEBO_COMPARATOR"},{"label":"Spiriva Respimat 2.5 μg","type":"OTHER"}],"summary":"Study Comparing the Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistent Asthma","primaryOutcome":{"measure":"Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4)","timeFrame":"Week 24","effectByArm":[{"arm":"GP MDI 28.8 μg","deltaMin":0.294,"sd":null},{"arm":"GP MDI 14.4 μg","deltaMin":0.284,"sd":null},{"arm":"GP MDI 7.2 μg","deltaMin":0.308,"sd":null},{"arm":"Placebo MDI","deltaMin":0.24,"sd":null},{"arm":"Spiriva Respimat 2.5 μg","deltaMin":0.347,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":9},"locations":{"siteCount":232,"countries":["United States"]},"refs":{"pmids":["36472162"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=PT001102&amp;attachmentIdentifier=16b78123-fc13-4fe3-9372-a54985c559e3&amp;fileName=PT001102_SAP_v1.0_2019_08_Redacted_05052020_PDFA.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=PT001102&amp;attachmentIdentifier=62b683f8-2d58-4502-8424-a59e8275b898&amp;fileName=PT001102_Protocol_Amendment_4_V_5.0_08Mar2019_Redacted_PDFA.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":235},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Sinusitis"]}}